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The  pro-Th2  cytokine  IL-33  is  now  emerging  as  an  important  Th1  cytokine-IFN- inducer  in  murine  CD4+
T cells  that is  essential  for  protective  cell-mediated  immunity  against  viral  infection  in  mice.  However,
whether  IL-33  can  promote  human  Th1  cell  differentiation  and  how  IL-33  polarizes  Th1 cells is less
understood.  We  assessed  the  ability  of IL-33  to induce  Th1  cell  differentiation  and  IFN-  production
in  vitro  and  in  vivo.  We  report  here  that  IL-33  alone  had  no  ability  in  Th1  cell  polarization.  However  it
potentiated  IL-12-mediated  Th1  cell  differentiation  and  IFN-  production  in  TCR-stimulated  murine  and
+
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L-33
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FN- production
human CD4 T cells  in  vitro and  in  vivo.  IL-33  promoted  Th1  cell  development  via  MyD88  and  synergized
with  IL-12  to  enhance  St2  and  IL-12R  expression  in  CD4+ T cells.
These  data  therefore  provide  a  novel  mechanism  for Th1 cell differentiation  and  optimal  induction  of
a Type  1 response.  Thus,  IL-33  is  capable  of inducing  IL-12-dependent  Th1  cell  differentiation  in  human
and  mouse  CD4+ T  cells.
©  2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).. Introduction
The recognition that CD4+ T cells can be differentiated into func-
ionally distinct subsets, including Th1 and Th2 cells, based on their
istinct proﬁle of cytokines to which they respond and secrete
fter stimulation, represented a major advance in immunology
Mosmann and Coffman, 1989; Sher and Coffman, 1992). Thus, IL-
2 produced by antigen-presenting cells (APCs), together with TCR
ctivation, drives the differentiation of CD4+ precursor T cells to Th1
ells which produce mainly IFN- and are important for defense
gainst intracellular pathogens but also mediate auto-immune
nﬂammation. IL-4 induces the differentiation of Th2 cells which
roduce mainly IL-4 and are associated with eradication of extra-
ellular parasites but also mediate allergic inﬂammation (Mosmann
Abbreviations: IL, interleukin; APC, antigen-presenting cells; RT, reverse tran-
cription; DLNs, draining lymph nodes.
∗ Corresponding author at: Institute of Infection, Immunity and Inﬂam-
ation, 120 University Place, University of Glasgow, Glasgow G12 8TA, UK.
ax: +44 141 330 4297.
E-mail address: Damo.Xu@glasgow.ac.uk (D. Xu).
1 Thease authors have contributed equally to the work.
ttp://dx.doi.org/10.1016/j.imbio.2015.11.013
171-2985/© 2015 The Authors. Published by Elsevier GmbH. This is an open access articand Coffman, 1989; Constant and Bottomly, 1997). Furthermore,
Th1 and Th2 cells counter-regulate each other’s function by the
relative concentration of the cytokines they produce. The balance
of the Th1 and Th2 response frequently determines the outcome
of several important infectious and autoimmune diseases (Seder
et al., 1993; Constant and Bottomly, 1997; O’Garra et al., 1997). It
is therefore of considerable importance to deﬁne the mechanisms
underlying the preferential induction of each of these T cell sub-
sets. The members of the IL-1 family including IL-1 and IL-18 are
closely associated with Th1 and Th2 cell differentiation (Xu et al.
1998a,b, 2000; Guo et al., 2009); we therefore investigated the role
of IL-33 (Schmitz et al., 2005), a member of the IL-1 cytokine family,
in the induction and regulation of Th1 cell development in vitro and
in vivo.
IL-33 is only produced by innate immune cells including epithe-
lial cells, DCs and macrophages (Schmitz et al., 2005; Rank et al.,
2009; Pichery et al., 2012), and is released most probably when cells
sense inﬂammatory signals or undergo necrosis (Moussion et al.,
2008; Cayrol and Girard, 2009). IL-33 signals via its receptor ST2
and co-receptor IL-1R accessory protein (IL-1RAcP) (Schmitz et al.,
2005; Ali et al., 2007; Chackerian et al., 2007). ST2 is expressed
on a wide-range of innate immune cells (Schmitz et al., 2005;
le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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rajkovic et al., 2004), but on limited adaptive immune cells pri-
arily Th2 cells (Xu et al., 1998a,b; Löhning et al., 1998). IL-33 is
 potent inducer of type 2 cytokines including IL-5 and IL-13 by
irectly activating ST2 on innate immune cells and Th2 cells, and
lays an important role in parasite infection, allergy and asthma
Schmitz et al., 2005; Kurowska-stolarska et al., 2008; Hamphreys
t al., 2008; Komai-Koma et al., 2012; Saglani et al., 2013). How-
ver, recent study suggests that IL-33 is also able to promote Th1
evelopment and function in mice (Baumann et al., 2015). We
ound previously that IL-33 can induce IFN- production in Th1-
ediated inﬂammatory arthritis and hyper-nociception in mice
Xu et al., 2008; Verri et al., 2008). However, whether IL-33 can
olarize human Th1 cells and the underlying mechanism by which
L-33 drives the Th1 development is less understood. We  therefore
tudied the effect and mechanism of IL-33 on Th1 cell development
n human and murine CD4+ T cells in vitro and in vivo.
. Materials and methods
.1. Mice
C57BL/6 mice were obtained from Harlan Olac (Bices-
er, Oxon, UK). St2−/− mice have been previously described
Kurowska-Stolarska et al., 2008). All mice were housed in speciﬁc-
athogen-free conditions at Glasgow University, UK, and mice of
–6 weeks old were used in the experiments. Procedures were
n accordance with the UK Home Ofﬁce animal experimentation
uidelines.
.2. Recombinant IL-33
Recombinant IL-33 (rIL-33) was obtained from PeproTech and
lso expressed in Escherichia coli and puriﬁed by Ni-NTA afﬁn-
ty chromatography as described previously (Kurowska-Stolarska
t al., 2008; Humphreys et al., 2008; Komai-Koma et al., 2012).
ndotoxin was removed by puriﬁcation with polymyxin B chro-
atography. The purity of rIL-33 was >97% by silver staining and
ndotoxin levels were <0.1 unit/g of protein by the Limulus
mebocyte Lysate QCL-1000 pyrogen test (Cambrex). rIL-33 from
eproTech showed similar results.
.3. Immunization and cytokine injection
Mice were immunized subcutaneously with 100 l of chicken
valbumin (OVA, Fraction V, Sigma–Aldrich) (130 g) adsorbed
o 1% alum (Brenntag Biosector) ±cytokines (1 g/mouse), rIL-12
PeproTech) or rIL-33 co-adsorbed to alum/OVA before inoculation
nto groups of mice. Boosting inoculations were performed in the
ame fashion 1 week later.
.4. Cytokine measurement
Mouse draining lymph nodes (DLNs), spleen and blood were col-
ected from mice at end of the experiments. Single cell suspensions
rom spleen or DLNs were cultured in 24-well plates at 4 × 106 cells
n 2 ml  per well and stimulated with medium alone or with different
ose of OVA peptide. After 72 h, supernatants were collected and
oncentrations of IFN- and IL-4 were measured by ELISA using
aired antibodies according to the manufacturer’s instructions (R
 D systems).
.5. CD4+ T cell puriﬁcation and cultureHuman cord blood was obtained from informed consented
others and peripheral blood mononuclear cells (PBMCs) were
solated by density gradient centrifugation through Lymphoprepiology 221 (2016) 412–417 413
(Nycomed). CD4+ T cells from human PBMC and murine spleen
were puriﬁed by negative selection (AutoMACS; MiltenyiBiotec). T
cells were cultured in RPMI 1640 supplemented with 10% FCS, 2 mM
l-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. Puri-
ﬁed CD4+ T cells (purity ≥98%, 2 × 106 cells/ml) were activated with
plate-bound anti-CD3 Abs (3 g/ml; BD Biosciences), rIL-12, and
different doses of rIL-33 or a combination of these cytokines for dif-
ferent times as indicated. Freshly isolated cells, DLNs or spleen of
immunized mice were cultured with different dose of OVA peptide
without cytokines for 1–3 days. The cells, cellular RNA and culture
supernatants were collected for analysis by ﬂow cytometry, PCR or
ELISA, respectively.
2.6. Flow cytometry
Cultured or freshly isolated cells from spleen were stim-
ulated with PMA  (500 ng/ml) and ionomycin (50 ng/ml; both
from Sigma–Aldrich) for 4 h; GolgiStop was added during the
ﬁnal 3 h. The cells were incubated with anti-mouse CD16/32 to
block non-speciﬁc Fc binding (BD Biosciences) followed sepa-
rately by PerCP-conjugated anti-CD3, anti-CD4, (BD Biosciences)
or appropriate isotype controls. Cells were then ﬁxed with
Cytoﬁx/Cytoperm buffer (BD Biosciences), permeabilized with
perm/wash buffer (BD Biosciences), and incubated with FITC-
conjugated anti-IFN-, PE-conjugated anti-IL-4 (all from BD
Biosciences) or isotype controls followed by incubation with sec-
ondary antibodies or streptavidin if necessary. The cells were
analysed on dual laser (488 nm & 633 nm)  FACSCalibur ﬂow
cytometer (Becton Dickinson, Mountain View, CA) using CellQuest
Pro software (Becton Dickinson, Mountain View, CA).
2.7. Antibody measurement
Blood samples were taken from groups of mice 10 days after
immunization with OVA with or without rIL-12 and rIL-33 adsorbed
to alum. OVA-speciﬁc IgG1 and IgG2a levels in plasma were mea-
sured using OptEIA ELISA kits (BD Biosciences).
2.8. qPCR
RNA was puriﬁed from cultured cells or tissue samples using the
RNeasy Mini Kit following the manufacturer’s instructions (Qia-
gen). Reverse Transcription (RT) of RNA into cDNA was  carried
out using High-Capacity cDNA Reverse Transcription Kits (Applied
Biosystems). Real-time PCR was performed using Fast SYBR Green
master mix  on a Prism 7900HT (Applied Biosystems).
2.9. Statistical analysis
Statistical evaluation of cell proportions, cytokine production,
and qPCR analysis was  performed using the two-tail unpaired
Student’s T-test. All data are expressed as mean ± SD. 5–7
mice/group/experiment. p < 0.05 was  considered statistically sig-
niﬁcant. All experiments were repeated at least 3 times.
3. Results
3.1. IL-33 potentiates IL-12-mediated Th1 cell polarization
in vitro
It was  reported previously that IL-33 can polarize virus-speciﬁc
Th1 cells in mice (Baumann et al., 2015). We  found that IL-33 alone
failed to induce IFN- secretion in CD4+ T cells in vitro (Fig. 1A).
We  sought next to investigate whether IL-33 and IL-12 can syner-
gise in Th1 cell differentiation from naïve CD4+ T cells. To test this
hypothesis, naïve CD4+ T cells isolated from WT  or ST2−/− mice
414 M. Komai-Koma et al. / Immunobiology 221 (2016) 412–417
Fig. 1. IL-33 enhances Th1 cell polarization via ST2 and IL-12. CD4+ T cells from WT,
ST2−/− mice (A) or human cord blood (B) were stimulated with anti-CD3 Abs with
or  without IL-33 (10 ng/ml) or IL-12(10 ng/ml) for 72 h. Supernatants IFN- and IL-4
concentrations were measured by ELISA. (C) Human CD4+ T cells were stimulated
as above and intracellular cytokines were determined using FACScan. Data are pre-
sented as mean ± SD, n = 5 mice/group, and are representative of three independent
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Fig. 2. Mechanism by which IL-33 enhances Th1 cell development in vitro. CD4+ T
cells  from WT or MyD88−/− mice were stimulated with anti-CD3 Abs in the presence
or  absence of IL-33, IL-12 or a combination of the cytokines. The supernatants were
collected for cytokine measurement by ELISA after 72 h culture (A) and cells collected
for the detection of T-bet and GATA3 (B), st2 and IL-12R (C, D) by qPCR. Data are
T cells, IL-33 failed to potentiate IL-12-induced IFN- secretion inxperiments. ∗p < 0.05 compared with PBS control and **p < 0.01 compared to IL-33
ontrols.
ere cultured under Th1 cell polarization conditions with anti-CD3
ntibody, with or without IL-12 or IL-33, alone or together, for 72 h.
s expected, IL-12 stimulated higher levels of IFN- (Fig. 1A) but
ot IL-4 production as expected (data not shown) in polarized CD4+
 cells from WT  and ST2−/− mice compared to cells cultured with-
ut IL-12 (Fig. 1A). IL-33 alone failed to stimulate the synthesis of
oth IFN- and IL-4 in WT  and ST2−/− cells (Fig. 1A and data not
hown). However, IL-33 further enhanced the synthesis of IFN-
nduced by IL-12 in an ST2-dependent manner (Fig. 1A). No IL-5,
L-13, IL-17 and IL-10 had been detected in the culture of IL-33 and
L-12 stimulated cells.
To determine if IL-33 and IL-12 are also capable of inducing the
ame cytokine response pattern in human T cells, antigen naïve
uman CD4+ T cells from cord blood were activated with anti-CD3
ntibody in the presence or absence of human IL-12, and graded
oses of IL-33 (0–5 ng/ml). Human T cells also produced enhanced
evels of IFN- (Fig. 1B) but not IL-4 (data not shown) in respond-
ng synergistically to the combined stimulation of IL-12 and IL-33
ompared to either IL-12 or IL-33 alone (Fig. 1B).
We  further determined whether the IL-33 and IL-12 syner-
istically enhanced IFN- production in CD4+ T cells was  due to
nhancing Th1 cell polarization by examining their production of
L-4 and IFN- using intracellular cytokine staining and FACS anal-
sis. Consistent with the cytokine ELISA data in Fig. 1B, IL-33 and
L-12 synergistically enhanced the population of human CD4+ T cell
hich selectively expressed IFN- but not IL-4 compared to the PBS
ontrol (Fig. 1C). Similar results were also obtained from murine
D4+ T cells (data not shown). These results suggest that IL-33
nhanced the polarization of Th1 but not Th2 cells in the presence
f IL-12.presented as mean ± SD, n = 5 pooled mice/group and are representative of three
independent experiments; ∗p < 0.05 compared with control, **p < 0.01 compared to
WT  controls.
3.2. The mechanism by which IL-33 potentiates IL-12-mediated
IFN- production
We  next investigated the mechanism by which IFN- produc-
tion is increased in the CD4+ T cells stimulated synergistically with
IL-33 and IL-12.
MyD88 pathway is required for IL-33 signalling (Schmitz et al.,
2005). We therefore investigated the importance of MyD88 in IL-
33-enhanced IFN- production and Th1 cell polarization in a 72 h
cell culture in vitro. As shown in Fig. 2A, compared to WT  CD4+CD4+ T cells from MyD88−/− mice. As expected IL-33 and IL-12 had
no signiﬁcant effect on IL-4 production in CD4+ T cells from both
WT and MyD88−/− mice.
unobiology 221 (2016) 412–417 415
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Fig. 3. IL-33 enhances Th1 cell polarization in vivo. Groups of C57BL/6 mice were
immunized and challenged with OVA in the presence or absence of IL-33 or IL-
12,  alone or together as described in Methods. The mice were sacriﬁced on day
10. (A) IFN- and IL-4 concentrations in OVA peptide-stimulated spleen cells were
measured by ELISA. (B) Intracellular staining for IFN- and IL-4 in CD4+ cells fromM. Komai-Koma et al. / Imm
T-bet and GATA3 play a critical role in the induction and regu-
ation of Th1 and Th2 cell development, respectively (Szabo et al.,
000; Zheng and Flavell, 1997). We  next investigated the involve-
ent of these transcription factors in IL-33 and IL-12-enhanced
h1 cell polarization and IFN- production in WT CD4+ T cells. IL-
2 alone induced the transcription of T-bet but not GATA3 36 h after
ulture (Fig. 2B). However, IL-33 alone or together with IL-12 failed
o induce or enhance both transcription factors (Fig. 2B).
We  reported previously that IL-18 and IL-12 synergistically
nhanced Th1 cell polarization by increasing each other’s recep-
or expression on CD4+ T cells (Xu et al., 1998a,b). We  determined
hether IL-33 and IL-12 worked in a similar way  in Th1 cell polar-
zation by analysing the expression of their receptors St2 and IL-12R
n vitro. Murine CD4+ T cells were activated with anti-CD3, with or
ithout IL-12 and IL-33, individually or together, for either 18 h
Fig. 2C) or 72 h (Fig. 2D); representing the early and late Th1 cell
olarization conditions, respectively. IL-33 increased the expres-
ion of St2, and IL-33 plus IL-12 synergistically enhanced both St2
nd IL-12R expression after 18 h culture compared to the con-
rols (Fig. 2C). However, after 72 h culture, the expression level
f St2 after IL-33 or IL-33 plus IL-12 stimulation was  signiﬁcantly
educed compared to control (Fig. 2D). While the IL-12R expres-
ion levels were still higher than control, the expression levels were
educed compared with 18 h culture and further reduced in the IL-
3 plus IL-12 group compared to IL-12 control group (Fig. 2D). These
esults therefore suggest that IL-33 and IL-12 may  increase Th1 cell
olarization and IFN- secretion in TCR-activated CD4+ T cells by
nhancing each other’s receptor expression at the early stages of
h1 cell polarization.
.3. IL-33 potentiates IL-12-mediated Th1 response in vivo
We  next investigated whether IL-33 and IL-12 could also
nhance Th1 cell development in a Th2 environment in vivo using
he OVA/alum immunization method, a classic model for inducing
h2 response (Ma  et al., 1996). C57BL/6 mice were immunized with
VA antigen in alum adjuvant, with or without IL-33 or IL-12, alone
r together and challenged with OVA (protocol in methods). Spleen,
raining lymph nodes (DLNs) and serum samples were collected 10
ays after immunization.
We ﬁrst examined the IFN- and IL-4 produced by spleen cells
ultured ex vivo from groups of mice immunized with OVA antigen
ith or without cytokines. Spleens were harvested and single-cell
uspensions were cultured with different doses of OVA peptide
ntigen for 48 h. Splenocytes from OVA/IL-12 group of mice pro-
uced increased concentrations of OVA-induced IFN- in culture
ompared to PBS-stimulated controls; which was further enhanced
n the IL-33/IL-12/OVA group (Fig. 3A). In contrast, IL-4 was not sig-
iﬁcantly induced among the groups in this context (Fig. 3A). As
xpected, IL-33 alone induced high (about 700–900 pg/ml) and IL-
3/IL-12 induced low (about 80–100 pg/ml) levels of OVA-speciﬁc
L-5 and IL-13 production in the culture as reported previously (data
ot shown and Kurowska-Stolarska et al., 2008).
We next quantiﬁed the levels of Th1 cells in the immunization
xperiment above. DLN cells from the groups of mice were cultured
ith OVA peptide antigen for 72 h and then stained for surface
D3, CD4 and intracellular IFN- and IL-4, respectively, ex vivo.
VA/IL-12 group slightly enhanced the proportion of CD3+CD4+
FN-+IL-4− Th1 cells (0.67%) in DLN cells compared to OVA (0.32%)
nd OVA/IL-33 (0.58%) groups (Fig. 3B). The proportion of Th1 cells
n the OVA/IL-12 group was further increased in the OVA/IL-12/IL-
3 group (7.13%; up to 23 fold that of the controls, Fig. 3B).We  further determined OVA-speciﬁc antibody proﬁle in the
erum samples. As shown in Fig. 3C, the OVA/IL-12 and OVA/IL-
2/IL-33 groups had more speciﬁc IgG2a than the OVA and
VA/IL-33 groups (Fig. 3C). In contrast, the OVA/IL-33 group of micethe  DLN. (C) OVA-speciﬁc antibody titers in the serum samples were measured by
ELISA. Data are means ± SD, n = 5 pooled mice/group, and are representative of three
independent experiments. *p < 0.05 and **p < 0.01 compared to OVA controls.
produced more OVA-speciﬁc IgG1 than the OVA  alone group, and
this was signiﬁcantly reduced in the OVA/IL-12 and the OVA/IL-
12/IL-33 groups (Fig. 3C). However, no signiﬁcant differences had
been identiﬁed between the OVA/IL-12 and OVA/IL-12/IL-33 groups
in the antibody levels in this experimental condition.
4. Discussion
Data reported in this study reveal a hitherto unrecognized effect
and mechanism by which IL-33, a pro-Th2 cytokine, promotes Th1
cell development in human and in mice. Therefore our results may
further explain its beneﬁcial effects against tumours and infec-
tion (Bonilla et al., 2012; Gao et al., 2013; Villarreal et al., 2014)
and also help explain its detrimental effects on Th1-mediated pro-
inﬂammatory disorders (Xu et al., 2008; Verri et al., 2008).
Our results suggest that IL-33 may  promote Th1 cell differen-
tiation by the following mechanisms; (1) IL-33 signals promoting
Th1 differentiation depends on IL-12 and ST2. This is evidenced by
the observation that IL-33 alone cannot polarize Th1 cells, but can
do so by potentiating IL-12 function in WT  but not ST2−/− CD4+
T cells. (2) It is unclear how IL-33 and IL-12 synergize in Th1 cell
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olarization. Our result suggests that IL-33 and IL-12 may do so
y enhancing both ST2 and IL-12R expression in early activated
D4+ T cells (Fig. 2C). Furthermore, we found that the enhanced
T2 expression induced by IL-33 and IL-12 was down-regulated
2 h after Th1 polarization in vitro. This is agreed with the previ-
us report that ST2 expression during late Th1 cell development
as decreased in vitro and in vivo (Baumann et al., 2015) and that
stablished Th2 but not Th1 cells express ST2 (Xu et al., 1998a,b;
öhning et al., 1998). These ﬁndings suggests that ST2 expression
s induced during early Th1 cell polarization in naïve CD4+ T cells
y IL-33 and IL-12 signalling which is gradually inhibited when
h1 cells fully mature (Fig. 3 and Xu et al., 1998a,b). Thus, while
t may  promote Th1 cell development, it is unlikely that IL-33 has
rofound effect on mature Th1 cells. (3) The signalling pathway by
hich IL-33 enhances Th1 polarization is still unknown. We  found
hat MyD88 is required for the IL-33 and IL-12-induced Th1 cell
evelopment and IFN- production. It is also reported that T-bet
ut not GATA3 is involved in the IL-33-promoted Th1 cell polar-
zation (Baumann et al., 2015). We  also found that IL-12 alone or
ogether with IL-33 enhanced T-bet but not GATA3 expression in
CR-activated CD4+ T cells. More studies are needed to understand
he precise signalling pathway that is involved in IL-33-potentiated
h1 cell development.
IL-12 and IL-4 reciprocally regulate Th1 or Th2 cell differentia-
ion and function (Sher and Coffman, 1992; Constant and Bottomly,
997; O’Garra et al., 1997). It is likely that IL-33 inducing Th1 or Th2
esponse depends on the cytokine milieu, in particular the balance
f IL-12 and IL-4 in vivo. As such, in the IL-12-dominant cytokine
ilieu, for instance, in the pro-inﬂammatory conditions or bacte-
ial/virus infection, secreted IL-33 may  potentiate IL-12-mediated
h1 cell differentiation (Constant and Bottomly, 1997; Boumann
t al., 2015). In the IL-4-dominant cytokine milieu, for example,
n allergy or parasite infection, IL-33 may  preferably promote Th2
ell development and function (Schmitz et al., 2005; Kurowska-
tolarska et al., 2008; Hamphreys et al., 2008; Komai-Koma et al.,
012). Therefore, IL-33 is a pleotropic cytokine in Th1 and Th2
ell development and contributes to both Th1 and Th2-mediated
mmunity and disorders depending on cytokine milieu.
While enhanced IL-12-mediated Th1 polarization in vivo, we
ound that IL-33 could not further potentiate IL-12-induced anti-
ody proﬁle in this experimental condition. This may  be because
L-33 alone can also polarize a Th2-like cell set which only produces
L-5 and IL-13, but not IL-4 as reported previously, and this cell set
s capable to induce Th2-like response in vivo (Kurowska-Stolarska
t al., 2008).
It is reported that IL-33 and IL-12 also synergistically enhances
c1 cell development in CD8+ T cells (Yang et al., 2011). However,
he effect and mechanism by which IL-33 enhances Th1 cell func-
ion in our study differs from that in Tc1 cells in at least two aspects;
1) IL-33 promotes Th1 differentiation from naïve T cells in our
xperiment but not Tc1 cell differentiation as in the previous report
Yang et al., 2011). (2) IL-33 can enhance established effector Tc1
ut not mature Th1 cell function (Yang et al., 2011). The likely expla-
ation for these differences is because ST2 expression is induced
nly in early TCR activated naïve CD4+ T cells which is then grad-
ally inhibited when Th1 cells fully mature (Fig. 3 and Xu et al.,
998a,b). In contrast, ST2 is only expressed on effector CD8+ T cells
r polarized Tc1 cells but not on naïve and early activated CD8+ T
ells (Yang et al., 2011). Nevertheless, these ﬁndings highlight the
otential importance for IL-33 to enhance an antigen-speciﬁc type
 response by promoting both Th1 and Tc1 cell function in adaptive
mmunity and in inﬂammatory disorders.The clinical relevance of the IL-33-enhanced Th1 cell develop-
ent in immunity and disease is unknown. Since IL-33 is induced
y many pathogens and inﬂammatory agents this novel Th1-
evelopment pathway may  play an important role in a wide-rangeiology 221 (2016) 412–417
of infectious and inﬂammatory disorders. Furthermore, IL-33 may
also serve as a novel adjuvant in vaccination against cancer and
infectious diseases.
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